# Study With Atu027 in Patients With Advanced Solid Cancer

> **NCT00938574** · PHASE1 · COMPLETED · sponsor: **Silence Therapeutics GmbH** · enrollment: 34 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** Atu027

## Key facts

- **NCT ID:** NCT00938574
- **Lead sponsor:** Silence Therapeutics GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2012-07
- **Final completion:** 2012-09
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2013-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00938574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00938574, "Study With Atu027 in Patients With Advanced Solid Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00938574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*